GT Biopharma stock reports USD 7.75 million financing update

GT Biopharma stock was trading at USD 7.00 on Nasdaq on September 24, 2026, down 1.41 percent from the previous close. The company has combined a new clinical milestone with a revised financing package that carries a USD 7.75 million purchase price.

Financing reaches USD 7.75 million

On September 18, 2026, GT Biopharma amended its Series M 10 percent convertible preferred stock placement and raised the aggregate purchase price to USD 7.75 million for 8,611.111 preferred shares, according to Stock Titan. The stated purchase price equals 87.72 percent of GT Biopharma's USD 8,835,092 market capitalization at the September 24 quote.

The financing is material relative to the equity value because the company remains in clinical development, where capital supports trials, regulatory work and platform development rather than commercial sales. That relationship makes dilution terms and conversion mechanics important variables alongside the pipeline update.

FDA clearance expands the pipeline

GT Biopharma said on September 15, 2026, that the FDA cleared an investigational new drug application for GTB-5550 in multiple myeloma under an investigator sponsored trial protocol, as reported in the company's press release. GTB-5550 is a B7-H3-targeted natural killer cell engager within the company's TriKE platform.

The regulatory step adds multiple myeloma to a development story that also includes blood cancers and solid tumors. For investors, the key distinction is between a cleared clinical pathway and a commercial product, since the former creates a development opportunity while still requiring trial execution and additional funding.

Stock remains below its yearly high

At USD 7.00 on September 24, 2026, GTBP was 79.56 percent below its 52-week high of USD 34.25 and USD 2.09 above its 52-week low of USD 4.91. Its intraday range was USD 6.78 to USD 7.03, placing the quote near the top of that session's range.

The Nasdaq-listed biotechnology company has a market capitalization of USD 8,835,092 and a current share price that reflects both the recent financing scale and the risk profile of an early-stage clinical pipeline.